AbbVie in talks to sell $5B women's drugs portfolio

  • AbbVie (NYSE:ABBV) is in discussions to sell a ~$5B portfolio of women's drugs it acquired last year through its purchase of Allergan , Reuters reports.
  • AbbVie is working with Morgan Stanley on an auction process that has attracted interest from private equity firms including CVC Capital Partners, according to the report.
  • The portfolio reportedly generates 12-month EBITDA of ~$500M and could be valued at ~10x its EBITDA.
  • AbbVie has been relying on its blockbuster Humira to drive up sales and beat forecasts, but with the drug's U.S. patent protection expiring in 2023, AbbVie needs to pay down a large debt amassed through the Allergan purchase in order to focus on new investments.

    Over the current book year the total revenue from the company in North Chicago will be 55.31 billion USD (consensus estimates). This is quite more than 2020's revenue of 45.8 billion USD.

    Historical revenues and results Abbvie plus estimates 2020

    historische koersen

    The analysts expect for 2021 a net profit of 22.14 billion USD. The majority of the analysts expects for this year a profit per share of 12.45 USD. The price/earnings-ratio is then 8.31.

    Huge dividend Abbvie

    For this year most of the analysts expect a dividend of 5.14 USD per share. Thus the dividend yield equals 4.97 percent. The average dividend yield of the biotech companies is a limited 0.37 percent.

    Abbvie 's market capitalization is around 152.95 billion USD. The Abbvie stock was the past 12 months quite unstable. Since last March the stock is even 54 percent higher. This year the stock price moved between 63 and 113 dollar.

    Historical stock prices Abbvie

    fundamental research abbvie

    Click here for dividend Abbvie. On Friday, the stock closed at 103.42 USD. Nieuwsdienst: +31 084-0032-842

    Copyright B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.